BMC Chemistry

Table 4 Cytotoxicity of compounds 1, 2, 3, 4, 5, 6, 7 and 8 against breast carcinoma cell line MCF-7

From: Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties

Concentration µg/mL	Viability (%)/compound
Concentration µg/mL	1	2	3	4	5	6	7	8
500	7.18	22.34	3.86	9.26	4.23	37.15	16.27	8.07
250	13.95	34.51	9.62	20.84	9.06	51.49	29.38	16.56
125	24.82	45.28	14.87	28.63	15.38	74.01	38.69	24.56
62.5	32.93	73.69	20.65	36.59	21.75	88.63	49.16	31.88
31.25	45.06	86.13	26.83	42.67	28.91	97.89	71.32	40.31
15.6	60.83	94.56	36.54	48.54	36.42	100	86.04	52.76
7.8	79.62	98.94	45.02	65.18	42.37	100	93.76	68.49
3.9	85.21	100	60.89	80.95	50.16	100	98.51	82.53
2	92.37	100	78.15	91.79	65.24	100	100	91.42
1	98.64	100	86.41	95.48	76.35	100	100	97.17
0	100	100	100	100	100	100	100	100

Back to article page

ISSN: 2661-801X

Contact us

Submission enquiries: bmcchemistry@biomedcentral.com
General enquiries: ORSupport@springernature.com